0437 GMT - Clarity Pharmaceuticals' bulls at Canaccord Genuity are even more confident in their buy call after asking around about the company's prostate-cancer theranostic. Canaccord's analysts tell clients in a note that their discussions with industry experts suggest that the market for Clarity's SAR-bisPSMA imaging agent is larger than investors anticipate. They expect positive results from a coming head-to-head trial, which they see addressing a key need for detection in patients with low prostate-specific antigen levels. They raise their forecast for PSMA PET imaging sales for the next three to five years to US$730 million, from US$520 million previously. Canaccord lifts its target price 34% to A$9.00. Shares are up 7.2% at A$4.19. ([email protected]) (END) Dow Jones NewswiresJuly 22, 2025 00:37 ET (04:37 GMT)
CU6 Price at posting:
$4.03 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)